Olesen Ole F, Lonnroth Anna, Mulligan Bernard
Health Directorate, DG Research, European Commission, Rue de la Loi 200, B-1049 Brussels, Belgium.
Vaccine. 2009 Jan 29;27(5):640-5. doi: 10.1016/j.vaccine.2008.11.064. Epub 2008 Dec 6.
The use of vaccines is saving millions of lives every year across the globe, but a number of important diseases such as HIV/AIDS, malaria, TB and hepatitis C continue to frustrate attempts to produce effective vaccines against them. Confronting these challenges will require new approaches and increased research efforts by the scientific community. The Sixth Framework Programme (FP6; 2002-2006) of the European Commission (EC) has been an important catalyst in this direction by allocating a financial contribution of more than EUR 210 million to a wide variety of vaccine research activities, ranging from basic vaccinology, translational research to clinical application of vaccines. Taken together, around 581 research groups from 52 countries are participating in the vaccine activities of FP6. This impressive number signals a new spirit of collaborative research, which will facilitate the exploitation of the immense possibilities in modern vaccinology.
疫苗的使用每年在全球拯救着数百万人的生命,但诸如艾滋病毒/艾滋病、疟疾、结核病和丙型肝炎等一些重要疾病仍使研发有效疫苗的努力受挫。应对这些挑战需要新的方法以及科学界加大研究力度。欧盟委员会(EC)的第六框架计划(FP6;2002 - 2006年)通过为从基础疫苗学、转化研究到疫苗临床应用等广泛的疫苗研究活动拨款超过2.1亿欧元,在这一方向上发挥了重要的推动作用。来自52个国家的约581个研究小组共同参与了FP6的疫苗相关活动。这一可观的数字彰显了合作研究的新精神,将有助于挖掘现代疫苗学中的巨大潜力。